
  
    
      
        Background_NNP
        Most_JJS current_JJ methods_NNS of_IN cancer_NN early_JJ detection_NN ,_, such_JJ as_IN
        mammography_NN or_CC cervical_JJ cytology_NN ,_, are_VBP based_VBN on_IN anatomic_JJ
        changes_NNS in_IN tissues_NNS or_CC morphologic_JJ changes_NNS in_IN cells_NNS ._.
        Recently_RB ,_, various_JJ molecular_JJ markers_NNS ,_, such_JJ as_IN protein_NN or_CC
        genetic_JJ changes_NNS have_VBP been_VBN proposed_VBN for_IN cancer_NN early_JJ
        detection_NN [_NN 1_CD 2_CD 3_CD 4_CD ]_NN ._. This_DT has_VBZ spurred_VBN many_JJ investigators_NNS
        with_IN long-term_JJ cohort_NN studies_NNS to_TO serially_RB collect_VB and_CC store_VB
        blood_NN or_CC tissue_NN specimens_NNS ._. The_DT aim_NN is_VBZ to_TO later_RB perform_VB a_DT
        nested-case_JJ control_NN study_NN ,_, where_WRB specimens_NNS from_IN subjects_NNS
        with_IN a_DT particular_JJ type_NN of_IN cancer_NN (_( cases_NNS )_) and_CC specimens_NNS from_IN
        a_DT random_JJ sample_NN of_IN subjects_NNS without_IN the_DT cancer_NN (_( controls_NNS )_)
        are_VBP tested_VBN for_IN various_JJ molecular_JJ markers_NNS ._. Sometime_RB this_DT
        sort_NN of_IN study_NN is_VBZ called_VBN a_DT retrospective_NN longitudinal_NN study_NN
        [_NN 6_CD ]_NN although_IN retrospective_NN longitudinal_NN data_NNS could_MD arise_VB
        in_IN other_JJ ways_NNS ,_, as_RB well_RB ._. Unlike_IN cross-sectional_JJ study_NN
        designs_NNS ,_, the_DT markers_NNS are_VBP measured_VBN on_IN specimens_NNS collected_VBN
        well_RB before_IN the_DT onset_NN of_IN clinical_JJ disease_NN in_IN cases_NNS ._. This_DT
        avoids_VBZ the_DT potential_JJ confounding_VBG effect_NN of_IN the_DT target_NN
        disease_NN on_IN the_DT marker_NN ._.
        For_IN example_NN ,_, in_IN the_DT ATBC_NNP (_( alpha-tocopherol_JJ ,_,
        beta-carotene_JJ )_) [_NN 7_CD ]_NN and_CC CARET_NNP [_NN 8_CD ]_NN studies_NNS ,_, subjects_NNS were_VBD
        randomized_JJ to_TO placebo_NN or_CC drug_NN to_TO in_IN a_DT long-term_JJ study_NN to_TO
        determine_VB the_DT effect_NN of_IN the_DT drug_NN on_IN lung_NN cancer_NN mortality_NN ._.
        During_IN the_DT course_NN of_IN the_DT trial_NN serum_NN was_VBD serially_RB collected_VBN
        and_CC stored_VBN in_IN a_DT biorepository_NN ._. In_IN a_DT subsequent_JJ nested_JJ
        case-control_JJ study_NN ,_, stored_VBD serum_NN samples_NNS from_IN all_DT cases_NNS of_IN
        prostate_NN cancer_NN and_CC a_DT random_JJ sample_NN of_IN controls_NNS were_VBD tested_VBN
        for_IN prostate-specific_JJ antigen_NN (_( PSA_NNP )_) ._.
        Importantly_NNP the_DT nested_JJ case-control_JJ study_NN of_IN early_JJ
        detection_NN biomarkers_NNS may_MD be_VB distinct_JJ from_IN the_DT original_JJ
        long-term_JJ study_NN from_IN which_WDT serum_NN were_VBD collected_VBN ._. It_PRP is_VBZ
        designed_VBN to_TO answer_VB a_DT different_JJ question_NN ,_, it_PRP typically_RB
        studies_VBZ subjects_NNS with_IN a_DT different_JJ disease_NN ,_, and_CC it_PRP often_RB
        ignores_VBZ the_DT intervention_NN in_IN the_DT original_JJ long-term_JJ
        study_NN ._.
      
      
        Methods_NNP
        We_PRP had_VBD three_CD considerations_NNS in_IN formulating_VBG appropriate_JJ
        guidelines_NNS ._. First_LS we_PRP wanted_VBD to_TO link_VB the_DT analysis_NN to_TO the_DT
        goal_NN of_IN study_NN ,_, namely_RB ,_, to_TO help_VB decide_VB on_IN further_JJ study_NN of_IN
        the_DT biomarker_NN as_IN a_DT trigger_NN for_IN early_JJ intervention_NN ._. Second_JJ
        we_PRP wanted_VBD to_TO minimize_VB possible_JJ biases_NNS in_IN the_DT selection_NN of_IN
        cases_NNS and_CC the_DT controls_NNS and_CC in_IN the_DT investigation_NN of_IN many_JJ
        markers_NNS ._. Third_NNP ,_, we_PRP wanted_VBD to_TO extract_VB as_IN much_JJ information_NN as_IN
        possible_JJ relevant_JJ to_TO the_DT evaluation_NN ._.
      
      
        Results_NNS
        We_PRP offer_VBP the_DT following_VBG guidelines_NNS for_IN the_DT design_NN and_CC
        analysis_NN of_IN nested_JJ case-control_JJ studies_NNS of_IN early_JJ detection_NN
        cancer_NN biomarkers_NNS ._.
        
          1_LS ._. For_IN the_DT clearest_NN interpretation_NN ,_,
          statistics_NNS for_IN binary_JJ markers_NNS should_MD be_VB based_VBN on_IN true_JJ and_CC
          false_JJ positive_JJ rates_NNS or_CC predictive_JJ values_NNS based_VBN on_IN the_DT
          true_JJ prevalence_NN -_: not_RB odds_NNS ratios_NNS ,_, relative_JJ risks_NNS ,_, or_CC
          predictive_JJ values_NNS based_VBN on_IN the_DT prevalence_NN in_IN the_DT
          study_NN 
        
        A_DT promising_JJ marker_NN should_MD have_VB a_DT high_JJ degree_NN of_IN accuracy_NN
        in_IN discriminating_VBG between_IN subjects_NNS who_WP are_VBP likely_JJ to_TO get_VB
        cancer_NN from_IN those_DT who_WP are_VBP not_RB ._. For_IN a_DT binary_JJ marker_NN ,_, which_WDT
        is_VBZ either_CC positive_JJ or_CC negative_JJ ,_, the_DT basic_JJ measures_NNS of_IN this_DT
        type_NN of_IN accuracy_NN are_VBP the_DT true_JJ positive_JJ and_CC false_JJ positive_JJ
        rates_NNS ._. Consider_VB the_DT hypothetical_JJ data_NN in_IN the_DT Table_NNP 1_CD from_IN a_DT
        nested_JJ case-control_JJ study_NN of_IN early_JJ detection_NN biomarkers_NNS ._.
        The_DT true_JJ positive_JJ rate_NN (_( TPR_NNP )_) ,_, or_CC the_DT test_NN sensitivity_NN ,_, is_VBZ
        the_DT probability_NN the_DT marker_NN is_VBZ positive_JJ given_VBN cancer_NN ._. The_DT
        false_JJ positive_JJ rate_NN (_( FPR_NNP )_) ,_, or_CC 1_CD -_: specificity_NN ,_, is_VBZ the_DT
        probability_NN the_DT marker_NN is_VBZ positive_JJ given_VBN no_DT cancer_NN ._. In_IN
        Table_NNP 1_CD ,_, TPR_NNP is_VBZ estimated_VBN by_IN 80_CD /_NN 100_CD =_SYM ._. 80_CD ,_, and_CC FPR_NNP is_VBZ
        estimated_VBN by_IN 10_CD /_NN 1000_CD =_SYM 01_CD ._. For_IN a_DT perfect_JJ test_NN ,_, TPR_NNP =_SYM 1_CD and_CC
        the_DT FPR_NNP =_SYM 0_CD ._. There_EX is_VBZ always_RB a_DT tradeoff_NN between_IN the_DT TPR_NNP and_CC
        FPR_NNP ,_, so_IN it_PRP is_VBZ meaningless_JJ to_TO assess_VB one_CD without_IN assessing_VBG
        the_DT other_JJ ._. For_IN example_NN ,_, one_PRP could_MD make_VB the_DT TPR_NNP equal_JJ to_TO 1_CD
        simply_RB by_IN classifying_VBG every_DT subject_NN as_IN positive_JJ for_IN cancer_NN ._.
        But_CC this_DT would_MD be_VB a_DT poor_JJ classification_NN rule_NN because_IN the_DT
        FPR_NNP would_MD also_RB be_VB 1_CD ._.
        
          Guidelines_NNS for_IN FPR_NNP and_CC TPR_NNP 
        
        Because_IN the_DT underlying_VBG prevalence_NN of_IN cancer_NN is_VBZ so_RB low_JJ in_IN
        average_JJ risk_NN populations_NNS ,_, for_IN acceptable_JJ cancer_NN screening_NN
        of_IN asymptomatic_JJ people_NNS ,_, the_DT FPR_NNP should_MD be_VB very_RB small_JJ [_NN 9_CD ]_NN
        ._. As_IN a_DT starting_NN point_NN we_PRP recommend_VBP basing_VBG guidelines_NNS for_IN
        FPR_NNP and_CC TPR_NNP on_IN the_DT FPR_NNP and_CC TPR_NNP for_IN mammography_NN ,_, which_WDT ,_, as_IN
        discussed_VBN below_IN ,_, is_VBZ FPR_NNP =_SYM ._. 01_CD and_CC TPR_NNP =_SYM ._. 80_CD ._. A_DT mammogram_NN is_VBZ
        analogous_JJ to_TO a_DT biomarker_NN test_NN for_IN cancer_NN but_CC there_EX is_VBZ extra_JJ
        information_NN from_IN various_JJ studies_NNS that_WDT makes_VBZ it_PRP useful_JJ for_IN
        setting_VBG guidelines_NNS ._.
        One_CD reason_NN for_IN using_VBG FPR_NNP and_CC TPR_NNP from_IN mammography_NN as_IN a_DT
        standard_NN is_VBZ that_IN ,_, unlike_IN biomarker_NN measurements_NNS in_IN nested_JJ
        case-control_JJ studies_NNS ,_, in_IN mammography_NN studies_NNS there_RB is_VBZ a_DT
        biopsy_NN at_IN the_DT time_NN of_IN a_DT positive_JJ test_NN ._. This_DT biopsy_NN is_VBZ the_DT
        gold_NN standard_JJ for_IN determining_VBG cancer_NN status_NN in_IN subjects_NNS
        with_IN positive_JJ mammograms_NNS and_CC is_VBZ used_VBN for_IN computing_NN TPR_NNP in_IN a_DT
        way_NN not_RB possible_JJ with_IN biomarkers_NNS in_IN nested_JJ case-control_JJ
        studies_NNS ._. The_DT TPR_NNP for_IN mammography_NN is_VBZ the_DT probability_NN of_IN a_DT
        positive_JJ biopsy_NN as_IN a_DT direct_JJ result_NN of_IN mammography_NN in_IN women_NNS
        with_IN cancer_NN and_CC is_VBZ estimated_VBN via_IN mathematical_JJ models_NNS or_CC
        data_NNS collected_VBN after_IN following_VBG subjects_NNS not_RB biopsied_JJ ._. As_IN
        discussed_VBN in_IN Baker_NNP and_CC Pinsky_NNP [_NN 10_CD ]_NN ,_, estimates_NNS ranged_VBD
        from_IN ._. 74_CD to_TO 1_CD ._. 00_CD with_IN ._. 80_CD a_DT conservative_JJ value_NN ._.
        Importantly_NNP the_DT estimated_VBN TPR_NNP for_IN mammography_NN is_VBZ not_RB
        likely_JJ to_TO be_VB affected_VBN by_IN overdiagnosis_NNS ,_, which_WDT means_VBZ that_IN
        some_DT screening-detected_JJ cancers_NNS would_MD never_RB have_VB caused_VBN
        medical_JJ problems_NNS during_IN the_DT patient_NN 's_POS life_NN [_NN 11_CD ]_NN ._. This_DT
        would_MD make_VB the_DT biomarker_NN appear_VBP more_RBR promising_JJ than_IN
        actually_RB the_DT case_NN ._. Results_NNS from_IN the_DT HIP_NNP screening_NN trial_NN of_IN
        mammography_NN and_CC clinical_JJ self-examination_JJ [_NN 12_CD ]_NN suggest_VBP
        that_IN if_IN there_EX were_VBD overdiagnosis_NNS with_IN mammography_NN ,_, it_PRP would_MD
        be_VB relatively_RB small_JJ ._. At_IN the_DT time_NN of_IN the_DT last_JJ breast_NN
        screening_NN in_IN the_DT HIP_NNP trial_NN ,_, there_EX were_VBD more_JJR cancers_NNS in_IN the_DT
        group_NN randomized_JJ to_TO screening_NN than_IN in_IN the_DT controls_NNS ._. But_CC
        with_IN further_JJ follow-up_JJ the_DT number_NN of_IN cancers_NNS in_IN the_DT control_NN
        group_NN eventually_RB equaled_VBD the_DT number_NN in_IN the_DT screened_VBD group_NN ,_,
        which_WDT would_MD not_RB have_VB occurred_VBN if_IN there_EX were_VBD substantial_JJ
        overdiagnosis_NNS ._.
        A_DT second_JJ reason_NN for_IN using_VBG FPR_NNP and_CC TPR_NNP from_IN mammography_NN
        is_VBZ that_IN ,_, based_VBN on_IN various_JJ randomized_JJ trials_NNS with_IN cancer_NN
        mortality_NN endpoint_NN ,_, mammography_NN is_VBZ generally_RB considered_VBN an_DT
        acceptable_JJ screening_NN modality_NN ._. The_DT implication_NN is_VBZ that_IN a_DT
        similar_JJ FPR_NNP and_CC TPR_NNP for_IN a_DT biomarker_NN would_MD lead_VB to_TO an_DT
        acceptable_JJ screening_NN modality_NN ._. For_IN a_DT particular_JJ biomarker_NN ,_,
        these_DT target_NN values_NNS of_IN FPR_NNP and_CC TPR_NNP from_IN mammography_NN may_MD
        need_VB modification_NN depending_VBG on_IN various_JJ factors_NNS ._. One_CD factor_NN
        is_VBZ the_DT invasiveness_NNS of_IN a_DT follow-up_JJ procedure_NN to_TO investigate_VB
        a_DT positive_JJ test_NN (_( e_SYM ._. g_SYM ._. needle_NN biopsy_NN of_IN the_DT prostate_NN to_TO
        investigate_VB an_DT abnormal_JJ PSA_NNP versus_CC laparotomy_NN to_TO
        investigate_VB an_DT abnormal_JJ CA_NNP 125_CD )_) ._. The_DT more_RBR invasive_JJ the_DT
        follow-up_JJ procedure_NN ,_, the_DT lower_VB the_DT FPR_NNP must_MD be_VB to_TO gain_VB
        acceptance_NN in_IN practice_NN ._. A_DT second_JJ factor_NN is_VBZ additional_JJ
        work-up_JJ prior_RB to_TO a_DT biopsy_NN ._. If_IN a_DT positive_JJ biomarker_NN is_VBZ
        unlikely_JJ to_TO trigger_VB additional_JJ diagnostic_JJ work-ups_JJ prior_RB to_TO
        biopsy_NN ,_, a_DT higher_JJR FPR_NNP might_MD be_VB acceptable_JJ ._.
        One_CD caveat_NN when_WRB using_VBG FPR_NNP from_IN mammography_NN is_VBZ to_TO be_VB
        careful_JJ as_IN to_TO its_PRP$ definition_NN ._. The_DT restricted_VBN definition_NN is_VBZ
        the_DT probability_NN of_IN a_DT positive_JJ biopsy_NN as_IN a_DT direct_JJ result_NN of_IN
        mammography_NN in_IN women_NNS without_IN cancer_NN ._. The_DT less_RBR restricted_JJ
        definition_NN is_VBZ the_DT probability_NN of_IN a_DT suspicious_JJ mammogram_NN
        warranting_VBG additional_JJ diagnostic_JJ follow-up_JJ of_IN any_DT type_NN in_IN
        women_NNS without_IN cancer_NN ._. Typically_RB nested-case_JJ control_NN studies_NNS
        of_IN early_JJ detection_NN biomarkers_NNS do_VBP not_RB provide_VB information_NN on_IN
        additional_JJ diagnostic_JJ follow-up_JJ ._. Therefore_RB they_PRP cannot_NN be_VB
        used_VBN to_TO estimate_VB a_DT less_RBR restricted_JJ FPR_NNP involving_VBG diagnostic_JJ
        follow-up_JJ ._. However_RB ,_, because_IN nested_JJ case-control_JJ biomarker_NN
        studies_NNS provide_VBP data_NNS on_IN cancer_NN diagnosis_NN ,_, they_PRP can_MD be_VB used_VBN
        to_TO estimate_VB a_DT more_RBR restricted_JJ FPR_NNP based_VBN on_IN unnecessary_JJ
        biopsies_NNS ._. Therefore_RB the_DT target_NN FPR_NNP is_VBZ based_VBN on_IN the_DT more_RBR
        restricted_JJ definition_NN of_IN FPR_NNP in_IN mammography_NN ._. For_IN
        mammography_NN the_DT more_RBR restricted_JJ FPR_NNP is_VBZ estimated_VBN by_IN the_DT
        fraction_NN of_IN women_NNS screened_VBD by_IN mammography_NN who_WP received_VBD a_DT
        biopsy_NN in_IN which_WDT no_DT cancer_NN was_VBD detected_VBN ._. As_IN discussed_VBN in_IN
        Baker_NNP and_CC Pinsky_NNP [_NN 10_CD ]_NN ,_, estimates_NNS of_IN FPR_NNP from_IN three_CD
        studies_NNS ranged_VBD from_IN ._. 005_CD to_TO ._. 013_CD with_IN a_DT middle_JJ value_NN of_IN
        around_IN ._. 010_CD ._.
        
          Inappropriateness_NNP of_IN odds_NNS ratio_NN and_CC
          relative_JJ risk_NN 
        
        When_WRB evaluating_VBG binary_JJ early_JJ detection_NN markers_NNS ,_, it_PRP is_VBZ
        inappropriate_JJ to_TO report_VB an_DT odds_NNS ratio_NN or_CC relative_JJ risk_NN ,_, as_IN
        is_VBZ common_JJ in_IN epidemiology_NN or_CC clinical_JJ trials_NNS ._. Because_IN an_DT
        odds_NNS ratio_NN or_CC relative_JJ risk_NN is_VBZ a_DT single_JJ number_NN ,_, it_PRP does_VBZ not_RB
        capture_VB the_DT tradeoff_NN between_IN correctly_RB classifying_VBG cancer_NN
        and_CC incorrectly_RB classifying_VBG non-cancers_JJ ._. Also_RB the_DT odds_NNS
        ratio_NN or_CC relative_JJ risk_NN can_MD lead_VB to_TO an_DT overoptimistic_JJ
        impression_NN of_IN the_DT performance_NN of_IN an_DT early_JJ detection_NN test_NN if_IN
        the_DT interpretation_NN is_VBZ based_VBN on_IN experience_NN in_IN epidemiology_NN
        or_CC clinical_JJ trials_NNS ._. In_IN the_DT latter_JJ settings_NNS an_DT odds_NNS ratio_NN of_IN
        3_CD is_VBZ often_RB considered_VBN large_JJ ._. Much_JJ larger_JJR odds_NNS ratio_NN are_VBP
        needed_VBN from_IN early_JJ detection_NN tests_NNS for_IN useful_JJ application_NN in_IN
        the_DT screening_NN setting_VBG [_NN 13_CD ]_NN ._. For_IN example_NN ,_, for_IN the_DT target_NN
        values_NNS of_IN FPR_NNP =_SYM ._. 01_CD and_CC TPR_NNP =_SYM ._. 80_CD ,_, the_DT odds_NNS ratio_NN equals_VBZ
        (_( TPR_NNP ×_NN (_( 1_CD -_: FPR_NNP )_) /_NN (_( (_( 1_CD -_: TPR_NNP )_) ×_NN FPR_NNP )_) =_SYM 396_CD ,_, as_IN in_IN Table_NNP 1_CD ._.
        
          Appropriate_NNP computation_NN of_IN predictive_JJ
          values_NNS 
        
        It_PRP is_VBZ sometimes_RB useful_JJ to_TO use_VB the_DT FPR_NNP and_CC TPR_NNP to_TO compute_VB
        the_DT predictive_JJ value_NN negative_JJ (_( PVN_NNP )_) ,_, the_DT probability_NN of_IN no_DT
        disease_NN if_IN the_DT marker_NN is_VBZ negative_JJ ,_, and_CC the_DT predictive_JJ value_NN
        positive_JJ (_( PVP_NNP )_) ,_, the_DT probability_NN of_IN disease_NN if_IN the_DT marker_NN is_VBZ
        positive_JJ ._. For_IN cancer_NN screening_NN ,_, it_PRP is_VBZ the_DT PVP_NNP that_WDT is_VBZ most_RBS
        important_JJ to_TO the_DT physician_NN in_IN clinical_JJ decision-making_NN ._.
        Because_IN the_DT likelihood_NN of_IN any_DT individual_JJ cancer_NN type_NN in_IN an_DT
        asymptomatic_JJ person_NN is_VBZ nearly_RB always_RB very_RB low_JJ ,_, a_DT negative_JJ
        early_JJ detection_NN test_NN usually_RB adds_VBZ little_JJ information_NN to_TO the_DT
        clinical_JJ impression_NN ._. The_DT computation_NN of_IN the_DT PVN_NNP and_CC PVP_NNP
        depend_VBP on_IN the_DT prevalence_NN of_IN cancer_NN as_RB well_RB as_IN on_IN the_DT FPR_NNP
        and_CC the_DT TPR_NNP ,_, as_IN shown_VBN below_IN ,_,
        PVP_NNP =_SYM (_( TPR_NNP ×_NN prevalence_NN )_) /_NN (_( TPR_NNP ×_NN prevalence_NN +_NN FPR_NNP
        (_( 1_CD -_: prevalence_NN )_) )_)
        PVN_NNP =_SYM (_( 1_CD -_: FPR_NNP )_) ×_NN (_( 1_CD -_: prevalence_NN )_) /_NN (_( (_( 1_CD -_: TPR_NNP )_) ×_NN prevalence_NN +_NN
        (_( 1_CD -_: FPR_NNP )_) (_( 1_CD -_: prevalence_NN )_) )_)
        When_WRB the_DT prevalence_NN is_VBZ small_JJ ,_, as_IN with_IN cancer_NN screening_NN ,_,
        a_DT small_JJ absolute_JJ change_NN in_IN FPR_NNP ,_, but_CC not_RB TPR_NNP ,_, can_MD have_VB a_DT
        large_JJ impact_NN on_IN the_DT PVP_NNP ._. It_PRP is_VBZ erroneous_JJ to_TO directly_RB
        compute_VB the_DT prevalence_NN from_IN data_NNS in_IN the_DT nested_JJ case-control_JJ
        study_NN ,_, as_IN in_IN Table_NNP 1_CD ,_, because_IN the_DT ratio_NN of_IN cases_NNS to_TO
        controls_NNS in_IN the_DT study_NN is_VBZ not_RB the_DT same_JJ as_IN in_IN the_DT population_NN ._.
        For_IN example_NN suppose_VBP FPR_NNP =_SYM ._. 01_CD ,_, TPR_NNP =_SYM ._. 80_CD ,_, and_CC prevalence_NN =_SYM
        ._. 003_CD ._. We_PRP obtain_VBP ,_,
        PVP_NNP =_SYM =_SYM (_( ._. 8_CD ×_NN ._. 003_CD )_) /_NN (_( ._. 8_CD ×_NN ._. 003_CD +_NN ._. 01_CD ._. 997_CD )_) =_SYM ._. 19_CD
        PVN_NNP =_SYM (_( ._. 99_CD ×_NN ._. 997_CD )_) /_NN (_( ._. 2_CD ×_NN ._. 003_CD +_NN ._. 99_CD ×_NN ._. 997_CD )_) =_SYM ._. 999_CD
        If_IN we_PRP had_VBD incorrectly_RB substituted_VBN the_DT apparent_JJ
        prevalence_NN in_IN Table_NNP 1_CD of_IN 100_CD /_NN 1100_CD =_SYM ._. 091_CD ,_, we_PRP would_MD have_VB
        incorrectly_RB computed_JJ PVP_NNP =_SYM ._. 89_CD and_CC PVN_NNP =_SYM ._. 980_CD ._. For_IN this_DT
        reason_NN ,_, calculation_NN and_CC reporting_NN of_IN PVP_NNP and_CC PVN_NNP using_VBG only_RB
        data_NNS from_IN a_DT nested_JJ case-control_JJ study_NN is_VBZ not_RB useful_JJ or_CC
        appropriate_JJ ._.
        
          Extension_NNP to_TO ordered_VBD categories_NNS via_IN ROC_NNP
          curves_NNS 
        
        Many_JJ markers_NNS for_IN the_DT early_JJ detection_NN of_IN cancer_NN can_MD be_VB
        reported_VBN as_IN ordered_VBN categories_NNS ._. Some_DT markers_NNS ,_, such_JJ as_IN
        sputum_NN cytology_NN ,_, inherently_RB involve_VB ordered_VBD categories_NNS ,_,
        such_JJ as_IN no_DT evidence_NN of_IN cancer_NN ,_, slight_JJ atypia_NN ,_, moderate_JJ
        atypia_NN ,_, severe_JJ atypia_NN ,_, and_CC frank_JJ cancer_NN ._. Other_JJ markers_NNS ,_,
        such_JJ as_IN PSA_NNP ,_, involve_VBP a_DT continuous_JJ measure_NN for_IN which_WDT higher_JJR
        values_NNS indicate_VBP a_DT greater_JJR probability_NN of_IN cancer_NN ._. Dividing_NNP
        these_DT continuous_JJ measures_NNS into_IN ranges_NNS (_( either_CC based_VBN on_IN
        predetermined_VBN values_NNS or_CC percentiles_NNS )_) gives_VBZ ordered_VBN
        categories_NNS ._.
        With_IN ordered_VBD categories_NNS ,_, the_DT statistics_NNS should_MD still_RB be_VB
        based_VBN on_IN FPR_NNP and_CC TPR_NNP ._. Each_DT ordered_VBN category_NN is_VBZ a_DT possible_JJ
        cutpoint_NN ,_, where_WRB values_NNS equal_JJ to_TO or_CC higher_JJR than_IN the_DT cutpoint_NN
        are_VBP called_VBN positive_JJ and_CC values_NNS lower_JJR than_IN the_DT cutpoint_NN are_VBP
        called_VBN negative_JJ ._. For_IN each_DT cutpoint_NN ,_, one_PRP can_MD compute_VB FPR_NNP and_CC
        TPR_NNP (_( Table_NNP 2_LS )_) and_CC generate_VB a_DT receiver-operating_JJ
        characteristic_JJ (_( ROC_NNP )_) curve_NN ,_, which_WDT is_VBZ a_DT plot_NN of_IN TPR_NNP versus_CC
        FPR_NNP for_IN the_DT various_JJ pairs_NNS [_NN 14_CD ]_NN ._. (_( See_VB Figure_NN 1_LS )_) ._. The_DT
        higher_JJR and_CC farther_RBR left_VBD the_DT points_NNS on_IN the_DT ROC_NNP curve_NN the_DT
        better_VB the_DT test_NN performance_NN ._. As_IN mentioned_VBN previously_RB ,_,
        acceptable_JJ cancer_NN screening_NN requires_VBZ very_RB small_JJ false_JJ
        positive_JJ rates_NNS ._. Therefore_RB ,_, for_IN evaluating_VBG cancer_NN
        biomarkers_NNS ,_, we_PRP are_VBP only_RB interested_JJ in_IN the_DT leftmost_NN sliver_NN
        of_IN the_DT ROC_NNP curve_NN in_IN Figure_NN 1_CD ._.
        
          2_LS ._. To_TO avoid_VB overdiagnosis_NNS bias_NN ,_, cases_NNS
          should_MD be_VB diagnosed_VBN as_IN a_DT result_NN of_IN symptoms_NNS rather_RB than_IN
          on_IN screening_NN 
        
        For_IN the_DT TPR_NNP in_IN the_DT biomarker_NN study_NN to_TO reflect_VB the_DT true_JJ
        TPR_NNP ,_, cases_VBZ should_MD be_VB diagnosed_VBN as_IN a_DT result_NN of_IN symptoms_NNS
        rather_RB than_IN on_IN screening_NN ._. For_IN example_NN in_IN the_DT study_NN of_IN PSA_NNP
        in_IN the_DT ATBC_NNP trial_NN [_NN 7_CD ]_NN ,_, cases_NNS were_VBD subjects_NNS diagnosed_VBN
        with_IN prostate_NN cancer_NN as_IN a_DT result_NN of_IN symptoms_NNS ._. If_IN the_DT
        prostate_NN cancer_NN cases_NNS were_VBD detected_VBN as_IN the_DT result_NN of_IN
        screening_NN ,_, say_VBP with_IN ultrasound_NN ,_, the_DT TPR_NNP could_MD be_VB
        artificially_RB elevated_VBD if_IN there_EX were_VBD overdiagnosis_NNS ,_, as_RB
        previously_RB discussed_VBN ._.
        
          3_LS ._. To_TO minimized_VBN selection_NN bias_NN ,_, the_DT
          spectrum_NN of_IN control_NN conditions_NNS should_MD be_VB the_DT same_JJ in_IN
          study_NN and_CC target_NN screening_NN populations_NNS 
        
        For_IN the_DT FPR_NNP in_IN the_DT nested_JJ case-control_JJ study_NN to_TO reflect_VB
        the_DT true_JJ FPR_NNP in_IN the_DT target_NN population_NN ,_, the_DT spectrum_NN of_IN
        control_NN conditions_NNS should_MD be_VB the_DT same_JJ as_IN in_IN the_DT target_NN
        population_NN ._. By_IN control_NN conditions_NNS ,_, we_PRP mean_VBP characteristics_NNS
        of_IN the_DT population_NN ,_, such_JJ as_IN the_DT presence_NN of_IN other_JJ diseases_NNS
        or_CC certain_JJ known_VBN risk_NN factors_NNS that_WDT could_MD elevate_NN the_DT false_JJ
        positive_JJ rate_NN ._.
        The_DT spectrum_NN of_IN conditions_NNS could_MD differ_VB considerably_RB if_IN
        the_DT retrospective_NN biomarker_NN study_NN were_VBD embedded_VBN in_IN a_DT
        randomized_JJ trial_NN with_IN strict_JJ eligibility_NN requirements_NNS ._. For_IN
        example_NN ,_, consider_VBP a_DT biomarker_NN for_IN the_DT early_JJ detection_NN of_IN
        lung_NN cancer_NN where_WRB the_DT data_NNS comes_VBZ from_IN a_DT biorepository_NN
        arising_VBG from_IN a_DT randomized_JJ trial_NN of_IN healthy_JJ subjects_NNS ._. It_PRP
        would_MD be_VB inappropriate_JJ to_TO apply_VB the_DT results_NNS to_TO a_DT population_NN
        with_IN a_DT high_JJ prevalence_NN of_IN chronic_JJ obstructive_JJ lung_NN disease_NN ,_,
        bronchitis_NNS ,_, or_CC viral_JJ pnuemonitis_NNS because_IN these_DT conditions_NNS
        could_MD increase_VB the_DT number_NN of_IN positive_JJ readings_NNS in_IN subjects_NNS
        without_IN lung_NN cancer_NN ._. Because_IN FPR_NNP is_VBZ very_RB small_JJ for_IN
        screening_NN to_TO be_VB acceptable_JJ ,_, this_DT spectrum_NN bias_NN could_MD have_VB
        important_JJ consequences_NNS in_IN a_DT clinical_JJ application_NN ._.
        It_PRP would_MD not_RB always_RB be_VB possible_JJ to_TO identify_VB all_DT relevant_JJ
        control_NN conditions_NNS ,_, but_CC to_TO the_DT extent_NN possible_JJ ,_, the_DT control_NN
        conditions_NNS should_MD be_VB similar_JJ in_IN both_DT populations_NNS ._.
        
          4_LS ._. To_TO extract_VB additional_JJ information_NN ,_,
          criteria_NNS for_IN a_DT positive_JJ test_NN should_MD be_VB based_VBN on_IN
          combinations_NNS of_IN individual_JJ markers_NNS and_CC changes_NNS in_IN marker_NN
          levels_NNS over_IN time_NN 
        
        Data_NNS from_IN multiple_JJ markers_NNS present_VB an_DT opportunity_NN to_TO
        extract_VB potentially_RB valuable_JJ information_NN not_RB available_JJ by_IN
        analyzing_VBG markers_NNS separately_RB ._. Consider_VB the_DT hypothetical_JJ
        data_NN in_IN Table_NNP 3_CD ._. The_DT left_VBN side_NN corresponds_NNS to_TO subjects_NNS
        without_IN cancer_NN ,_, and_CC the_DT right_JJ corresponds_NNS to_TO subjects_NNS with_IN
        cancer_NN ._. In_IN our_PRP$ idealized_JJ circumstance_NN ,_, markers_NNS A_DT and_CC B_NNP are_VBP
        independent_JJ for_IN subjects_NNS without_IN cancer_NN and_CC are_VBP perfectly_RB
        correlated_JJ for_IN subjects_NNS with_IN cancer_NN ._. The_DT indicated_VBN region_NN
        for_IN A_DT =_SYM 2_CD or_CC A_DT =_SYM 3_CD and_CC B_NNP =_SYM 2_CD or_CC B_NNP =_SYM 3_CD designates_VBZ a_DT positive_JJ
        test_NN that_WDT has_VBZ FPR_NNP =_SYM ._. 04_CD and_CC the_DT TPR_NNP =_SYM ._. 80_CD ._. Suppose_VB that_DT
        marker_NN A_DT and_CC marker_NN B_NNP were_VBD evaluated_VBN separately_RB ._. The_DT
        indicated_VBN region_NN corresponding_JJ to_TO A_DT only_RB ,_, namely_RB A_DT =_SYM 2_CD or_CC A_DT
        =_SYM 3_CD and_CC the_DT indicated_VBN region_NN corresponding_JJ to_TO B_NNP only_RB ,_,
        namely_RB B_NNP =_SYM 2_CD and_CC B_NNP =_SYM 3_CD ,_, each_DT designates_VBZ a_DT positive_JJ test_NN
        that_WDT has_VBZ FPR_NNP =_SYM ._. 20_CD and_CC TPR_NNP =_SYM ._. 80_CD ._. Thus_RB ,_, in_IN this_DT particular_JJ
        example_NN ,_, the_DT combination_NN of_IN markers_NNS leads_VBZ to_TO a_DT much_RB better_JJR
        test_NN than_IN the_DT separate_JJ markers_NNS ,_, with_IN a_DT smaller_JJR FPR_NNP (_( ._. 04_CD
        versus_CC ._. 20_CD )_) for_IN the_DT same_JJ TPR_NNP of_IN ._. 80_CD ._. One_PRP could_MD create_VB a_DT
        similar_JJ example_NN with_IN any_DT number_NN of_IN marker_NN levels_NNS ._. For_IN an_DT
        ideal_JJ test_NN in_IN which_WDT FPR_NNP =_SYM 0_CD and_CC TPR_NNP =_SYM 1_CD ,_, the_DT region_NN would_MD
        encompass_VB all_DT subjects_NNS with_IN cancer_NN but_CC no_DT subjects_NNS without_IN
        cancer_NN ._.
        A_DT real_JJ application_NN of_IN how_WRB marker_NN combinations_NNS provide_VBP
        extra_JJ information_NN comes_VBZ from_IN a_DT recent_JJ study_NN by_IN Mok_NNP et_CC al_NN [_NN
        15_CD ]_NN on_IN CA_NNP 125_CD and_CC Prostasin_NNP as_IN markers_NNS for_IN ovarian_NN cancer_NN ._.
        Although_IN the_DT data_NNS are_VBP not_RB from_IN a_DT nested_JJ case-control_JJ study_NN
        and_CC have_VBP not_RB been_VBN validated_JJ in_IN subsequent_JJ studies_NNS ,_, they_PRP are_VBP
        useful_JJ for_IN illustration_NN ._. Based_VBN on_IN Figure_NN 5_CD of_IN Mok_NNP et_CC al_NN [_NN
        15_CD ]_NN with_IN approximate_JJ values_NNS for_IN the_DT outpoints_NNS ,_, we_PRP
        investigated_VBD regions_NNS with_IN FPR_NNP =_SYM ._. 02_CD ._. The_DT combination_NN for_IN a_DT
        positive_JJ test_NN of_IN CA_NNP 125_CD greater_JJR than_IN or_CC equal_JJ to_TO 40_CD U_NNP /_NN ml_NN
        and_CC Prostasin_NNP greater_JJR than_IN or_CC equal_JJ to_TO 5_CD μg_NN /_NN ml_NN had_VBD FPR_NNP =_SYM
        ._. 02_CD and_CC TPR_NNP =_SYM ._. 92_CD ._. Evaluating_VBG CA_NNP 125_CD alone_RB ,_, the_DT criterion_NN
        for_IN a_DT positive_JJ test_NN of_IN CA_NNP 125_CD greater_JJR than_IN 80_CD U_NNP /_NN ml_NN had_VBD
        FPR_NNP =_SYM ._. 02_CD and_CC TPR_NNP =_SYM ._. 78_CD ._. Evaluating_VBG Prostasin_NNP alone_RB ,_, the_DT
        criterion_NN for_IN a_DT positive_JJ test_NN of_IN Prostasin_NNP greater_JJR than_IN 15_CD
        μg_NN /_NN ml_NN had_VBD FPR_NNP =_SYM ._. 02_CD and_CC TPR_NNP =_SYM ._. 32_CD ._. Thus_RB ,_, in_IN this_DT real_JJ
        example_NN ,_, the_DT combination_NN of_IN markers_NNS led_VBN to_TO a_DT better_JJR test_NN
        than_IN the_DT separate_JJ markers_NNS ,_, with_IN a_DT larger_JJR TPR_NNP (_( ._. 92_CD versus_CC
        ._. 78_CD or_CC ._. 32_CD )_) for_IN the_DT same_JJ FPR_NNP of_IN ._. 02_CD ._.
        To_TO more_RBR generally_RB compare_VB performance_NN of_IN a_DT combination_NN
        of_IN markers_NNS with_IN a_DT single_JJ marker_NN ,_, we_PRP need_VBP to_TO compare_VB ROC_NNP
        curves_NNS ._. Creating_NNP an_DT ROC_NNP curve_NN from_IN a_DT combination_NN of_IN markers_NNS
        is_VBZ different_JJ from_IN creating_VBG an_DT ROC_NNP curve_NN from_IN a_DT single_JJ
        marker_NN ._. With_IN a_DT combination_NN of_IN markers_NNS ,_, the_DT number_NN of_IN
        possible_JJ regions_NNS ,_, as_IN in_IN Table_NNP 3_CD a_DT ,_, for_IN calling_VBG a_DT marker_NN
        positive_NN is_VBZ extremely_RB large_JJ ._. Some_DT choices_NNS of_IN regions_NNS
        correspond_VB to_TO AND_CC rules_NNS ,_, for_IN example_NN A_DT >_NN 1_CD and_CC B_NNP >_NN 1_CD ,_, as_IN
        in_IN Table_NNP 3_CD a_DT ._. Some_DT choices_NNS of_IN regions_NNS correspond_VB to_TO OR_NNP
        rules_NNS ,_, for_IN example_NN A_DT >_NN 2_CD or_CC B_NNP >_NN 2_CD ._. Other_JJ choices_NNS are_VBP also_RB
        possible_JJ ,_, but_CC for_IN biological_JJ reasons_NNS ,_, one_PRP would_MD usually_RB
        require_VB all_DT regions_NNS to_TO be_VB contiguous_JJ ._. A_DT plot_NN of_IN the_DT FPR_NNP and_CC
        TPR_NNP for_IN each_DT region_NN would_MD lead_VB to_TO a_DT cloud_NN of_IN points_NNS ,_, rather_RB
        than_IN the_DT smooth_JJ curve_NN in_IN Figure_NN 1_CD ._. To_TO create_VB the_DT best_JJS ROC_NNP
        curve_NN ,_, one_PRP should_MD select_VB those_DT points_NNS that_WDT are_VBP highest_JJS and_CC
        farthest_JJS to_TO the_DT left_NN ,_, which_WDT is_VBZ generally_RB all_DT that_WDT would_MD
        need_VB to_TO be_VB presented_VBN and_CC only_RB for_IN small_JJ false_JJ positive_JJ
        rates_NNS ._. For_IN complicated_VBN situations_NNS ,_, Baker_NNP [_NN 16_CD ]_NN proposed_VBD an_DT
        algorithm_NN to_TO select_VB the_DT regions_NNS creating_VBG the_DT best_JJS ROC_NNP curve_NN
        without_IN the_DT need_NN to_TO enumerate_NN all_DT the_DT regions_NNS ._.
        Mathematically_NNP ,_, in_IN any_DT sample_NN of_IN data_NNS ,_, the_DT best_JJS ROC_NNP curve_NN
        for_IN a_DT combination_NN of_IN markers_NNS must_MD be_VB as_IN good_JJ or_CC better_JJR than_IN
        the_DT ROC_NNP curve_NN for_IN any_DT of_IN the_DT markers_NNS evaluated_VBN separately_RB ._.
        The_DT reason_NN is_VBZ that_IN the_DT set_NN of_IN possible_JJ regions_NNS for_IN calling_VBG
        a_DT combination_NN of_IN markers_NNS positive_JJ includes_VBZ as_IN a_DT special_JJ
        case_NN the_DT regions_NNS for_IN calling_VBG any_DT single_JJ marker_NN
        positive_JJ ._.
        Alternative_NNP approaches_NNS that_WDT do_VBP not_RB directly_RB optimize_NN the_DT
        ROC_NNP curve_NN include_VBP linear_JJ logistic_JJ regression_NN or_CC linear_JJ
        discriminant_NN analysis_NN [_NN 17_CD ]_NN ,_, which_WDT choose_VBP regions_NNS based_VBN
        on_IN linear_JJ combinations_NNS of_IN the_DT markers_NNS ,_, and_CC neural_NN networks_NNS
        [_NN 18_CD ]_NN ,_, which_WDT choose_VBP regions_NNS in_IN a_DT very_RB complicated_VBN
        nonlinear_NN manner_NN ._. Due_JJ to_TO the_DT potential_NN for_IN overfitting_VBG (_( to_TO
        follow_VB )_) ,_, it_PRP is_VBZ not_RB possible_JJ to_TO make_VB a_DT blanket_NN statement_NN as_IN
        to_TO which_WDT approach_VBP for_IN choosing_VBG regions_NNS is_VBZ best_JJS ._. If_IN one_CD
        takes_VBZ the_DT set_NN of_IN regions_NNS for_IN calling_VBG a_DT combination_NN positive_JJ
        that_WDT gives_VBZ a_DT good_JJ ROC_NNP curve_NN in_IN a_DT random_JJ sample_NN of_IN data_NNS ,_, it_PRP
        may_MD give_VB a_DT poor_JJ ROC_NNP curve_NN in_IN another_DT random_JJ sample_NN of_IN the_DT
        data_NNS ,_, simply_RB due_JJ to_TO selecting_VBG chance_NN patterns_NNS in_IN the_DT first_JJ
        sample_NN ._. As_IN discussed_VBN in_IN the_DT section_NN on_IN overfitting_VBG ,_, this_DT
        motivates_NNS splitting_NN the_DT data_NNS into_IN two_CD random_JJ samples_NNS ,_,
        training_NN and_CC test_NN ,_, and_CC using_VBG the_DT regions_NNS from_IN the_DT training_NN
        sample_NN to_TO compute_VB the_DT definitive_JJ ROC_NNP curve_NN based_VBN on_IN data_NNS in_IN
        the_DT test_NN sample_NN ._.
        Changes_NNS in_IN marker_NN values_NNS over_IN time_NN also_RB provide_VB
        potentially_RB valuable_JJ information_NN not_RB available_JJ when_WRB
        examining_VBG markers_NNS at_IN a_DT single_JJ time_NN point_NN ._. With_IN marker_NN
        measurements_NNS at_IN two_CD different_JJ times_NNS per_IN subject_JJ (_( and_CC
        approximately_RB the_DT same_JJ interval_NN between_IN times_NNS )_) ,_, a_DT common_JJ
        summary_NN measure_NN is_VBZ the_DT slope_NN ._. If_IN investigators_NNS believe_VBP that_IN
        both_DT slope_NN and_CC baseline_NN level_NN predict_VBP cancer_NN ,_, the_DT
        combination_NN can_MD be_VB evaluated_VBN using_VBG the_DT previously_RB discussed_VBN
        methods_NNS for_IN evaluating_VBG multiple_JJ markers_NNS ,_, namely_RB ,_, treating_VBG
        baseline_NN level_NN and_CC slope_NN as_RB two_CD "_'' separate_JJ "_'' markers_NNS ._. With_IN
        measurements_NNS at_IN more_JJR than_IN two_CD times_NNS per_IN subject_JJ ,_,
        investigators_NNS may_MD identify_VB a_DT more_RBR complicated_JJ feature_NN ,_, such_JJ
        as_IN whether_IN or_CC not_RB there_EX is_VBZ a_DT sudden_JJ increase_NN in_IN marker_NN
        levels_NNS [_NN 19_CD ]_NN ._.
        When_WRB biomarker_NN measurements_NNS occur_VBP at_IN regular_JJ time_NN
        intervals_NNS (_( and_CC allowing_VBG different_JJ numbers_NNS of_IN measurements_NNS
        for_IN each_DT subject_JJ )_) ,_, one_PRP can_MD estimate_VB TPR_NNP and_CC FPR_NNP by_IN using_VBG a_DT
        first_JJ order_NN Markov_NNP chain_NN in_IN reverse_NN time_NN ,_, as_IN described_VBN by_IN
        Baker_NNP and_CC Tockman_NNP [_NN 20_CD ]_NN for_IN the_DT analysis_NN of_IN precancerous_JJ
        lesions_NNS for_IN lung_NN cancer_NN ._.
        
          5_LS ._. To_TO avoid_VB overfitting_VBG ,_, the_DT criteria_NNS for_IN
          a_DT positive_JJ marker_NN combination_NN developed_VBN in_IN a_DT training_NN
          sample_NN should_MD be_VB evaluated_VBN in_IN a_DT random_JJ test_NN sample_NN from_IN
          the_DT same_JJ study_NN and_CC ,_, if_IN possible_JJ ,_, a_DT validation_NN sample_NN from_IN
          another_DT study_NN ._. 
        
        With_IN a_DT single_JJ marker_NN and_CC a_DT large_JJ number_NN of_IN subjects_NNS ,_,
        there_EX is_VBZ usually_RB no_DT concern_NN with_IN overfitting_VBG ._. However_RB with_IN
        many_JJ combinations_NNS of_IN markers_NNS ,_, overfitting_VBG could_MD invalidate_NN
        results_NNS ._. Overfitting_NNP is_VBZ often_RB associated_VBN with_IN step-wise_JJ
        regression_NN models_NNS [_NN 21_CD ]_NN but_CC it_PRP can_MD occur_VB in_IN other_JJ
        situations_NNS as_RB well_RB ._. Overfitting_NNP of_IN a_DT larger_JJR number_NN of_IN
        markers_NNS to_TO a_DT relatively_RB small_JJ number_NN of_IN subjects_NNS produces_VBZ a_DT
        model_NN that_WDT is_VBZ overly_RB sensitive_JJ to_TO chance_NN fluctuations_NNS in_IN
        the_DT data_NNS ._. As_IN a_DT simple_JJ example_NN ,_, overfitting_VBG occurs_VBZ when_WRB a_DT
        sports_NNS announcer_NN reports_NNS that_IN a_DT baseball_NN player_NN had_VBD a_DT very_RB
        high_JJ batting_NN average_JJ against_IN left-handed_JJ pitchers_NNS in_IN
        ballpark_NN X_NNP over_IN the_DT past_JJ month_NN ._. This_DT average_NN is_VBZ not_RB very_RB
        reliable_JJ for_IN future_JJ predictions_NNS because_IN the_DT particular_RB set_NN
        of_IN factors_NNS ,_, left-handed_JJ pitchers_NNS and_CC ballpark_NN X_NNP ,_, were_VBD
        selected_VBN to_TO give_VB a_DT high_JJ average_NN ._. In_IN reality_NN the_DT high_JJ
        average_NN is_VBZ more_RBR likely_JJ the_DT result_NN of_IN chance_NN factors_NNS that_WDT
        coincided_VBD with_IN left_VBD handed_VBN pitchers_NNS at_IN ballpark_NN X_NNP during_IN
        that_DT particular_JJ month_NN ._. One_CD way_NN to_TO adjust_VB for_IN overfitting_VBG is_VBZ
        to_TO apply_VB the_DT factors_NNS in_IN another_DT sample_NN not_RB used_VBD for_IN initial_JJ
        reporting_NN ._. The_DT first_JJ sample_NN is_VBZ known_VBN as_IN the_DT training_NN
        sample_NN ,_, and_CC the_DT second_JJ sample_NN is_VBZ known_VBN as_IN the_DT test_NN sample_NN ._.
        For_IN example_NN ,_, the_DT prediction_NN of_IN the_DT average_NN against_IN left_VBD
        handed_VBN pitchers_NNS in_IN the_DT ballpark_NN X_NNP could_MD be_VB tested_VBN on_IN data_NNS
        from_IN a_DT different_JJ month_NN ._. Similarly_RB ,_, a_DT standard_JJ statistical_JJ
        approach_NN to_TO adjust_VB for_IN overfitting_VBG is_VBZ to_TO randomly_RB split_VB the_DT
        data_NNS into_IN a_DT training_NN and_CC test_NN samples_NNS ._. This_DT is_VBZ called_VBN the_DT
        split-sample_JJ approach_NN ._. Promising_NNP marker_NN combinations_NNS are_VBP
        identified_VBN in_IN the_DT training_NN sample_NN ,_, but_CC more_RBR reliable_JJ FPR_NNP
        and_CC TPR_NNP measurements_NNS are_VBP made_VBN in_IN the_DT test_NN sample_NN because_IN it_PRP
        involves_VBZ different_JJ data_NNS ._. Baker_NNP [_NN 16_CD ]_NN used_VBD the_DT split-sample_JJ
        approach_NN to_TO evaluate_VB the_DT performance_NN of_IN four_CD markers_NNS for_IN
        prostate_NN cancer_NN ._.
        More_RBR sophisticated_JJ adjustments_NNS for_IN overfitting_VBG include_VBP
        cross-validation_JJ and_CC bootstrapping_VBG ._. Suppose_VB the_DT interest_NN
        lies_VBZ in_IN a_DT single_JJ statistic_NN ,_, such_JJ as_IN the_DT area_NN under_IN the_DT part_NN
        of_IN the_DT ROC_NNP curve_NN corresponding_JJ to_TO a_DT small_JJ FPR_NNP ._. In_IN a_DT typical_JJ
        cross-validation_JJ analysis_NN (_( i_NNP )_) the_DT data_NNS are_VBP randomly_RB split_NN
        into_IN ten_CD samples_NNS each_DT with_IN 10_CD %_NN of_IN the_DT data_NNS ,_, (_( ii_NN )_) one_CD of_IN the_DT
        10_CD %_NN samples_NNS is_VBZ deleted_VBN ,_, (_( iii_NN )_) the_DT statistic_NN is_VBZ computed_JJ by_IN
        applying_VBG the_DT classification_NN rule_NN recalculated_VBD from_IN the_DT
        remaining_VBG 90_CD %_NN of_IN the_DT sample_NN to_TO the_DT deleted_VBN 10_CD %_NN sample_NN and_CC
        (_( iv_NN )_) an_DT average_NN is_VBZ taken_VBN of_IN the_DT statistic_NN over_IN all_DT ten_CD 10_CD %_NN
        samples_NNS [_NN 22_CD ]_NN ._. Although_IN one_PRP could_MD use_VB a_DT different_JJ
        fraction_NN than_IN 10_CD %_NN ,_, ROC_NNP computation_NN it_PRP is_VBZ not_RB possible_JJ with_IN
        the_DT most_RBS extreme_JJ version_NN of_IN cross-validation_JJ that_WDT involves_VBZ
        leaving_VBG out_IN one_CD subject_JJ at_IN a_DT time_NN ._. With_IN bootstrapping_VBG ,_, (_( i_NNP )_)
        the_DT entire_JJ data_NN set_VBN is_VBZ resampled_JJ with_IN replacement_NN many_JJ
        times_NNS ,_, (_( ii_NN )_) on_IN each_DT resampling_VBG the_DT statistics_NNS is_VBZ computed_JJ ,_,
        and_CC (_( iii_NN )_) the_DT statistics_NNS from_IN each_DT resampling_VBG are_VBP combined_VBN
        in_IN a_DT special_JJ way_NN [_NN 22_CD ]_NN ._. In_IN a_DT recent_JJ study_NN comparing_VBG these_DT
        adjustments_NNS with_IN other_JJ types_NNS of_IN statistics_NNS in_IN a_DT different_JJ
        setting_NN ,_, Steyerberg_NNP et_CC al_NN [_NN 22_CD ]_NN found_VBD that_IN the_DT
        split-sample_JJ approach_NN tended_VBD to_TO underestimate_NN performance_NN ,_,
        cross-validation_JJ performed_VBN poorly_RB on_IN some_DT statistics_NNS that_WDT
        were_VBD not_RB normally_RB distributed_VBN ,_, and_CC bootstrapping_VBG performed_VBN
        best_JJS overall_JJ ._. For_IN our_PRP$ purposes_NNS of_IN estimating_VBG an_DT entire_JJ ROC_NNP
        curve_NN rather_RB than_IN a_DT summary_NN statistic_NN ,_, more_JJR research_NN is_VBZ
        needed_VBN for_IN cross-validation_JJ and_CC bootstrapping_VBG ,_, as_IN it_PRP is_VBZ not_RB
        clear_JJ how_WRB best_JJS to_TO combine_VB ROC_NNP curves_NNS over_IN different_JJ
        samples_NNS ._.
        Regardless_RB of_IN the_DT method_NN used_VBN to_TO adjust_VB for_IN overfitting_VBG
        in_IN forming_VBG a_DT classification_NN rule_NN ,_, to_TO obtain_VB the_DT most_RBS
        reliable_JJ FPR_NNP and_CC TPR_NNP measurements_NNS ,_, the_DT classification_NN rule_NN
        should_MD ideally_RB be_VB evaluated_VBN in_IN a_DT 
        validation_NN sample_NN from_IN a_DT 
        different_JJ study_NN ,_, as_IN in_IN Baker_NNP [_NN 16_CD ]_NN
        ._.
        
          6_CD ._. To_TO identify_VB biomarkers_NNS with_IN true_JJ and_CC
          false_JJ positive_JJ rates_NNS similar_JJ to_TO mammography_NN ,_, the_DT
          training_NN ,_, test_NN ,_, and_CC validation_NN samples_NNS should_MD each_DT
          include_VB at_IN least_JJS 110_CD randomly_RB selected_VBN subjects_NNS without_IN
          cancer_NN and_CC 70_CD subjects_NNS with_IN cancer_NN (_( as_IN based_VBN on_IN FPR_NNP and_CC
          TPR_NNP for_IN mammography_NN )_) 
        
        The_DT sample_NN size_NN is_VBZ based_VBN on_IN the_DT need_NN to_TO determine_VB if_IN the_DT
        biomarker_NN is_VBZ sufficiently_RB promising_JJ for_IN investigation_NN as_IN a_DT
        trigger_NN for_IN early_JJ intervention_NN in_IN a_DT future_JJ trial_NN ._. As_IN
        discussed_VBN previously_RB ,_, based_VBN on_IN considerations_NNS from_IN
        mammography_NN ,_, our_PRP$ target_NN values_NNS are_VBP FPR_NNP =_SYM ._. 01_CD and_CC TPR_NNP =_SYM ._. 80_CD ._.
        In_IN most_JJS situations_NNS ,_, we_PRP think_VBP it_PRP would_MD be_VB of_IN interest_NN to_TO
        specify_VB a_DT 95_CD %_NN confidence_NN interval_NN for_IN TPR_NNP of_IN (_( ._. 70_CD ,_, ._. 90_CD )_) ._.
        Using_VBG a_DT normal_JJ approximation_NN the_DT target_NN standard_JJ error_NN is_VBZ
        approximately_RB ._. 05_CD ._. Setting_VBG the_DT standard_JJ error_NN of_IN TPR_NNP ,_, TPR_NNP ×_NN
        (_( 1_CD -_: TPR_NNP )_) /_NN (_( square_JJ root_NN of_IN n_NN )_) ,_, equal_JJ to_TO ._. 05_CD and_CC solving_VBG for_IN
        the_DT sample_NN size_NN n_NN ,_, we_PRP obtain_VBP n_NN =_SYM 64_CD ,_, which_WDT we_PRP round_VBP up_IN to_TO
        70_CD ._. In_IN addition_NN we_PRP think_VBP that_IN in_IN most_JJS situations_NNS the_DT
        largest_JJS reasonable_JJ value_NN of_IN FPR_NNP would_MD be_VB ._. 03_CD which_WDT is_VBZ 3_CD
        times_NNS the_DT number_NN of_IN false_JJ positives_NNS as_IN with_IN mammography_NN
        screening_NN ._. Because_IN FPR_NNP is_VBZ so_RB small_JJ ,_, we_PRP do_VBP not_RB use_VB a_DT normal_JJ
        approximation_NN ._. We_PRP specify_VB a_DT sample_NN size_NN of_IN n_NN =_SYM 110_CD ,_, so_IN that_IN
        under_IN the_DT binomial_NN distribution_NN with_IN FPR_NNP =_SYM ._. 01_CD ,_, the_DT upper_JJ
        2_CD ._. 5_CD %_NN bound_VBN equals_VBZ ._. 03_CD ×_NN 110_CD ._. Strictly_RB ,_, these_DT sample_NN sizes_NNS
        apply_VBP only_RB after_IN a_DT single_JJ criterion_NN for_IN a_DT positive_JJ test_NN has_VBZ
        been_VBN identified_VBN ._. For_IN a_DT training_NN sample_NN ,_, one_PRP might_MD consider_VB
        larger_JJR sample_NN sizes_NNS ._.
      
      
        Conclusion_NNP
        A_DT major_JJ advantage_NN of_IN nested_JJ case-control_JJ studies_NNS for_IN
        early_JJ detection_NN biomarkers_NNS is_VBZ that_IN they_PRP can_MD be_VB done_VBN quickly_RB
        if_IN serum_NN from_IN a_DT long-term_JJ study_NN has_VBZ been_VBN stored_VBN in_IN a_DT
        biorepository_NN ._. Importantly_NNP the_DT retrospective_NN aspect_NN does_VBZ
        not_RB compromise_VB the_DT validity_NN ._. There_EX are_VBP none_NN of_IN the_DT usual_JJ
        problems_NNS with_IN retrospective_NN studies_NNS such_JJ as_IN recall_NN bias_NN ._.
        Thus_RB we_PRP anticipate_VBP that_IN in_IN the_DT coming_VBG years_NNS ,_, there_EX will_MD be_VB
        many_JJ reports_NNS in_IN literature_NN from_IN studies_NNS of_IN this_DT design_NN ._.
        These_DT guidelines_NNS should_MD greatly_RB help_VB investigators_NNS
        design_NN and_CC analyze_VB nested_JJ case-control_JJ studies_NNS for_IN early_JJ
        detection_NN biomarkers_NNS and_CC help_VB readers_NNS of_IN the_DT literature_NN to_TO
        interpret_VB them_PRP ._. It_PRP bears_VBZ emphasis_NN that_IN these_DT studies_NNS do_VBP not_RB
        prove_VB clinical_JJ efficacy_NN of_IN the_DT markers_NNS ._. Rather_RB ,_, they_PRP
        suggest_VBP which_WDT markers_NNS or_CC marker_NN combinations_NNS are_VBP the_DT most_RBS
        promising_JJ candidates_NNS for_IN further_JJ study_NN as_IN a_DT trigger_NN for_IN
        early_JJ intervention_NN in_IN definitive_JJ trials_NNS with_IN
        cancer-mortality_JJ endpoints_NNS ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD
      
    
  
